Try our mobile app

Switch to company model in classical logic    *

General information

Country: UNITED STATES

Sector: Biotechnology

Vor Biopharma, Inc., a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company`s VOR33 eHSCs lacks CD33, a protein that is expressed by AML blood cancer cells. The company`s eHSCs targeted therapies, such as CAR-Ts, bispecific antibodies, and antibody-drug conjugates provide treatment for blood cancers. Vor Biopharma, Inc. has a collaboration agreement with Akron BioProducts to develop and manufacture cGMP nucleases. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Website: vorbio.com



Growth: Bad revenue growth rate 0.0%, are preserved at an average historical level 0.0%. The revenue growth dynamics is unstable

Profitability: LTM EBITDA margin is negative, 0.0%. In the last quarter the company did not beat the estimated EPS. The company was ahead of estimated EPS in 40% of quarters (showing a gain of $0 per share on average)

Cash Flow Generation: Dividend yield for the last twelve months 0.0%. Free cash flow yield -99.9% (LTM)

Entry Point: Share price is 19 232.5% higher than minimum and 40.0% lower than maximum for the last 3 years

Insiders: For the last 3 months insiders sold company shares on $24.2 mln (-104.634% of cap.)

Key Financials (Download financials)

Ticker: VOR
Share price, USD:  (-3.2%)29.25
year average price 3.54  


year start price 0.72 2024-10-17

min close price 0.15 2025-05-09

max close price 48.72 2025-09-30

current price 29.25 2025-10-16
Common stocks: 6 263 572

Dividend Yield:  0.0%
EV / Sales: 200.0x
Margin (EBITDA LTM / Revenue):
Fundamental value created in LTM:
Market Cap (mln): 183
Net Debt (mln): -61
EV (Enterprise Value): 122
Price to Book: 2.6x

Revenue and EBITDA

Quarterly values (mln)

Change (y/y)

Cash Flow

FCF (mln)

Net Debt / Cash and Equivalents (mln)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / Sales

Potential dynamics

News


2025-09-25seekingalpha.com

Vor Biopharma: Transformed Company Is A High Risk Buy On Autoimmune Disease Promise

2025-09-17prnewswire.com

Results of China Phase III Clinical Study of Telitacicept for Generalized Myasthenia Gravis Selected for Oral Presentation at 2025 AANEM Annual Meeting

2025-09-17globenewswire.com

Vor Bio Announces Oral Presentation of 48-Week China Phase 3 Generalized Myasthenia Gravis Clinical Study at AANEM

2025-09-12globenewswire.com

Vor Bio to Participate in the Stifel 2025 Virtual Immunology and Inflammation Forum

2025-07-21globenewswire.com

Vor Bio Appoints Biotech Industry Leaders Alexander (Bo) Cumbo and Michel Detheux, Ph.D. to Board of Directors

2025-06-30benzinga.com

Vor Biopharma's RemeGen Deal Paves Way For Multi-Billion Dollar Autoimmune Market

2025-06-30zacks.com

Vor Bio Stock Skyrockets 250% in the Past Week: Here's Why

2025-06-25globenewswire.com

Vor Bio Announces $175 Million Private Placement

2025-02-13globenewswire.com

Vor Bio Presents Novel Research Highlighting Opportunities and Challenges Facing Institutions Enrolling Patients in Cell and Gene Therapy Trials

2024-12-27globenewswire.com

Vor Bio Announces $55.6 Million Private Placement
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol VOR VOR VOR VOR VOR VOR VOR VOR VOR
reportedCurrency USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2024-11-07 2024-08-08 2024-08-08 2024-03-20 2023-11-07 2023-08-10 2023-05-11 2023-03-23 2022-11-10
acceptedDate 2024-11-07 16:01:41 2024-08-08 16:01:36 2024-08-08 16:13:36 2024-03-20 16:00:52 2023-11-07 16:00:33 2023-08-10 16:01:27 2023-05-11 16:02:37 2023-03-23 16:05:16 2022-11-10 16:06:18
calendarYear 2024 2024 2024 2023 2023 2023 2023 2022 2022
period Q3 Q2 Q1 Q4 Q3 Q2 Q1 Q4 Q3
revenue 0 0 0 12M 0 0 0 0 0
costOfRevenue 0 900 000 943 000 892 000 2M 1M 0 0 0
grossProfit 0 -900 000 -943 000 11M -2M -1M 0 0 0
grossProfitRatio 0 0 0 0.927 0 0 0 0 0
researchAndDevelopmentExpenses 22M 22M 24M 21M 28M 24M 22M 17M 17M
generalAndAdministrativeExpenses 7M 7M 8M 7M 8M 8M 9M 8M 7M
sellingAndMarketingExpenses 0 -900 000 -943 000 -892 000 0 0 0 0 0
sellingGeneralAndAdministrativeExpenses 7M 6M 7M 6M 8M 8M 9M 8M 7M
otherExpenses 0 0 0 0 0 0 0 0 0
operatingExpenses 29M 28M 31M 27M 35M 32M 30M 25M 24M
costAndExpenses 29M 29M 32M 28M 35M 32M 30M 25M 24M
interestIncome 954 000 1M 2M 2M 2M 2M 2M 815 000 313 000
interestExpense 0 0 0 2M 0 0 -2M -1M 313 000
depreciationAndAmortization 851 000 900 000 943 000 892 000 -1M 3M 837 000 632 000 892 000
ebitda -28M -29M -31M -27M -35M -29M -30M -24M -23M
ebitdaratio 0 0 0 -2.227 0 0 0 0 0
operatingIncome -29M -29M -32M -28M -35M -32M -30M -25M -24M
operatingIncomeRatio 0 0 0 -2.3 0 0 0 0 0
totalOtherIncomeExpensesNet 954 000 1M 2M 2M 2M 2M 2M 815 000 313 000
incomeBeforeTax -28M -28M -31M -26M -33M -30M -28M -24M -24M
incomeBeforeTaxRatio 0 0 0 -2.148 0 0 0 0 0
incomeTaxExpense 0 0 899 724 565 000 1M 0 -2M -1M -313 000
netIncome -28M -28M -31M -26M -33M -30M -26M -23M -23M
netIncomeRatio 0 0 0 -2.148 0 0 0 0 0
eps -0.4 -0.41 -0.45 -0.39 -0.49 -0.45 -0.4 -0.58 -0.62
epsdiluted -0.4 -0.41 -0.45 -0.39 -0.49 -0.45 -0.4 -0.58 -0.62
weightedAverageShsOut 68M 68M 68M 68M 68M 67M 66M 40M 38M
weightedAverageShsOutDil 68M 68M 68M 68M 68M 67M 66M 40M 38M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link

Balance Sheet Statement

Property 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol VOR VOR VOR VOR VOR VOR VOR VOR VOR
reportedCurrency USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2024-11-07 2024-08-08 2024-08-08 2024-03-20 2023-11-07 2023-08-10 2023-05-11 2023-03-23 2022-11-10
acceptedDate 2024-11-07 16:01:41 2024-08-08 16:01:36 2024-08-08 16:13:36 2024-03-20 16:00:52 2023-11-07 16:00:33 2023-08-10 16:01:27 2023-05-11 16:02:37 2023-03-23 16:05:16 2022-11-10 16:06:18
calendarYear 2024 2024 2024 2023 2023 2023 2023 2022 2022
period Q3 Q2 Q1 Q4 Q3 Q2 Q1 Q4 Q3
cashAndCashEquivalents 53M 76M 45M 31M 45M 32M 42M 58M 61M
shortTermInvestments 10M 10M 63M 106M 115M 155M 168M 173M 75M
cashAndShortTermInvestments 63M 86M 107M 137M 160M 187M 210M 230M 136M
netReceivables 0 0 0 0 0 0 0 0 0
inventory 0 0 0 0 0 0 0 0 0
otherCurrentAssets 4M 4M 4M 4M 667 000 539 000 459 000 2M 2M
totalCurrentAssets 67M 90M 112M 141M 164M 191M 217M 237M 143M
propertyPlantEquipmentNet 44M 46M 48M 50M 52M 54M 55M 57M 58M
goodwill 0 0 0 0 0 0 0 0 0
intangibleAssets 0 0 0 0 0 0 0 0 0
goodwillAndIntangibleAssets 0 0 0 0 0 0 0 0 0
longTermInvestments 0 2M 2M 2M 2M 2M 0 0 0
taxAssets 0 0 0 12M 0 0 0 0 0
otherNonCurrentAssets 5M 3M 5M 5M 4M 3M 5M 5M 5M
totalNonCurrentAssets 49M 51M 55M 69M 59M 60M 61M 62M 64M
otherAssets 0 1 0 0 0 0 0 0 0
totalAssets 116M 142M 167M 210M 223M 251M 278M 299M 206M
accountPayables 1M 2M 2M 815 000 1M 2M 3M 2M 824 000
shortTermDebt 4M 8M 4M 4M 4M 4M 4M 3M 4M
taxPayables 0 0 0 0 0 0 0 0 0
deferredRevenue 0 0 0 0 10M 7M 0 0 0
otherCurrentLiabilities 9M 4M 7M 11M 419 000 268 000 6M 8M 7M
totalCurrentLiabilities 14M 14M 13M 16M 15M 13M 13M 13M 11M
longTermDebt 29M 30M 31M 32M 33M 34M 35M 36M 37M
deferredRevenueNonCurrent 0 0 0 0 0 0 0 0 0
deferredTaxLiabilitiesNonCurrent 0 0 0 12M 0 0 0 0 0
otherNonCurrentLiabilities 0 0 -1 0 0 0 0 0 32M
totalNonCurrentLiabilities 29M 30M 31M 44M 33M 34M 35M 36M 37M
otherLiabilities 0 0 1 0 0 0 0 0 0
capitalLeaseObligations 33M 34M 31M 32M 37M 38M 38M 39M 40M
totalLiabilities 43M 44M 44M 59M 48M 47M 47M 49M 48M
preferredStock 0 0 0 0 0 0 0 0 0
commonStock 7000 7000 7000 7000 7000 7000 7000 7000 4000
retainedEarnings -426M -399M -371M -340M -314M -281M -251M -222M -198M
accumulatedOtherComprehensiveIncomeLoss 68 000 -70 000 -87 000 -77 000 -280 000 -436 000 -174 000 -770 000 -1M
othertotalStockholdersEquity 499M 497M 494M 491M 489M 486M 481M 474M 358M
totalStockholdersEquity 73M 98M 123M 151M 175M 204M 230M 251M 159M
totalEquity 73M 98M 123M 151M 175M 204M 230M 251M 159M
totalLiabilitiesAndStockholdersEquity 116M 142M 167M 210M 223M 251M 278M 299M 206M
minorityInterest 0 0 0 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 116M 142M 167M 210M 223M 251M 278M 299M 206M
totalInvestments 10M 12M 65M 108M 115M 155M 168M 173M 75M
totalDebt 33M 34M 35M 36M 37M 38M 38M 39M 40M
netDebt -20M -42M -10M 4M -8M 5M -4M -19M -21M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link

Cash Flow Statement

Property 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol VOR VOR VOR VOR VOR VOR VOR VOR VOR
reportedCurrency USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2024-11-07 2024-08-08 2024-08-08 2024-03-20 2023-11-07 2023-08-10 2023-05-11 2023-03-23 2022-11-10
acceptedDate 2024-11-07 16:01:41 2024-08-08 16:01:36 2024-08-08 16:13:36 2024-03-20 16:00:52 2023-11-07 16:00:33 2023-08-10 16:01:27 2023-05-11 16:02:37 2023-03-23 16:05:16 2022-11-10 16:06:18
calendarYear 2024 2024 2024 2023 2023 2023 2023 2022 2022
period Q3 Q2 Q1 Q4 Q3 Q2 Q1 Q4 Q3
netIncome -28M -28M -31M -26M -33M -30M -28M -24M -24M
depreciationAndAmortization 820 000 900 000 943 000 892 000 -1M 3M 837 000 632 000 892 000
deferredIncomeTax 0 0 0 -4M 5M 1M 0 0 0
stockBasedCompensation 2M 3M 3M 2M 3M 4M 4M 4M 3M
changeInWorkingCapital 3M 1M -4M -779 000 1M 2M -1M -1M -874 000
accountsReceivables 0 0 0 0 0 0 0 0 0
inventory 0 0 0 0 0 0 0 0 0
accountsPayables 485 000 551 000 -2M 172 000 3M 107 000 -88 000 0.812 0
otherWorkingCapital 2M 857 000 -2M -951 000 -1M 2M 88 000 -1M 0
otherNonCashItems -2M 5M 8M 4M -3M -4M 751 000 2M 2M
netCashProvidedByOperatingActivities -23M -22M -30M -24M -28M -24M -24M -18M -19M
investmentsInPropertyPlantAndEquipment -34 000 -9000 -114 000 -111 000 -465 000 -399 000 -94 000 -321 000 -298 000
acquisitionsNet 0 0 0 61 631 -41 001 -14 038 0 0 0
purchasesOfInvestments 0 -1000 -10M -17M 1000 -35M -23M -118M 0
salesMaturitiesOfInvestments 0 53M 54M 27M 41M 49M 30M 21M 13M
otherInvestingActivites 0 0 44M -1 41 001 14 038 0 0 0
netCashUsedForInvestingActivites -34 000 53M 44M 10M 41M 14M 6M -97M 13M
debtRepayment 0 0 0 0 0 0 0 0 0
commonStockIssued 111 000 -92 000 278 000 47 000 392 000 579 000 4M 112M 4M
commonStockRepurchased 0 0 -182 000 -22 -220 -545 -400 000 0 0
dividendsPaid 0 0 0 0 0 0 0 0 0
otherFinancingActivites -70 000 61 000 -182 000 -22 000 -215 780 -360 455 -703 000 631 000 234 000
netCashUsedProvidedByFinancingActivities 41 000 -31 000 96 000 25 000 176 000 218 000 3M 112M 4M
effectOfForexChangesOnCash 0 0 0 -5M -10M 14M 0 0 0
netChangeInCash -21M 31M 14M -14M 13M -38M -15M -3M -2M
cashAtEndOfPeriod 55M 76M 45M 31M 47M 4M 45M 60M 63M
cashAtBeginningOfPeriod 76M 45M 31M 45M 35M 42M 60M 63M 65M
operatingCashFlow -23M -22M -30M -24M -28M -24M -24M -18M -19M
capitalExpenditure -34 000 -9000 -114 000 -111 000 -465 000 -399 000 -94 000 -321 000 -298 000
freeCashFlow -23M -22M -31M -24M -28M -24M -24M -19M -19M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link

Earning call transcript

Press-releases

Show financial reports only

2024-09-30 11:00 ET
Vor Bio Appoints Seasoned Healthcare Institutional Investor, Han Choi, M.D., LL.M., as Chief Financial Officer
2024-09-05 20:01 ET
New Clinical Data Validates Vor Bio’s Approach of Using Shielded Transplants to Deliver Targeted Therapies
2024-08-08 20:05 ET
Vor Bio Reports Second Quarter 2024 Financial Results and Provides Company Update
2024-08-02 20:01 ET
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2024-07-09 20:01 ET
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2024-06-04 20:01 ET
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2024-05-09 20:05 ET
Vor Bio Reports First Quarter 2024 Financial Results and Provides Company Update
2024-05-06 12:00 ET
Vor Bio to Participate in Upcoming Investor Conferences
2024-05-03 20:01 ET
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2024-05-02 20:01 ET
Vor Bio Appoints Accomplished Oncology and Cancer Immunotherapy R&D Executive, Fouad Namouni, M.D., to its Board of Directors
2024-04-01 12:00 ET
Vor Bio to Participate in Upcoming Investor Conferences
2024-03-20 20:05 ET
Vor Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update
2024-03-05 21:01 ET
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2024-03-04 13:00 ET
Vor Bio to Participate in Upcoming Investor Conferences
2024-02-07 13:00 ET
Vor Bio to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference
2024-02-02 21:01 ET
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2024-01-17 21:01 ET
Vor Bio Doses First AML Patient with VCAR33 (ALLO) and Provides Corporate Update
2023-12-21 21:01 ET
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2023-12-01 21:01 ET
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2023-11-27 13:00 ET
Vor Bio to Participate in the JMP Securities Hematology and Oncology Summit
2023-11-09 21:01 ET
Vor Bio Presents Positive Data Update on Trem-cel at HSCT² Conference
2023-11-07 21:05 ET
Vor Bio Reports Third Quarter 2023 Financial Results and Provides Company Update
2023-11-03 20:01 ET
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2023-11-03 12:00 ET
Vor Bio to Participate in Upcoming Investor Conferences
2023-11-02 13:01 ET
Multiple Clinical and Preclinical Presentations at ASH 2023 Highlight Vor Bio’s Novel eHSC and CAR-T Platform
2023-10-03 20:01 ET
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2023-09-25 12:00 ET
Vor Bio to Participate in Upcoming Investor Conferences
2023-08-30 12:00 ET
Vor Bio to Participate in Upcoming Investor Conferences
2023-08-10 20:05 ET
Vor Bio Reports Second Quarter 2023 Financial Results and Provides Company Update
2023-08-01 12:00 ET
Vor Bio to Participate in the Wedbush PacGrow Healthcare Conference
2023-06-09 11:30 ET
Successful Primary Engraftment of Trem-cel in First Five AML Patients Demonstrates Promise of Vor Bio’s Platform
2023-06-05 12:00 ET
Vor Bio to Participate in the Goldman Sachs Healthcare Conference
2023-05-11 20:05 ET
Vor Bio Reports First Quarter 2023 Financial Results and Provides Company Update
2023-04-18 12:00 ET
Vor Bio to Participate in Upcoming Investor Conferences
2023-03-23 20:01 ET
Vor Bio Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Company Update
2023-02-21 13:00 ET
Vor Bio to Participate in Upcoming Investor Conferences
2023-02-16 17:00 ET
First AML Patient Transplanted with Vor Bio’s Trem-cel Demonstrated Durable Engraftment through Multiple Mylotarg™ Cycles at Initial Dose Level
2023-01-19 13:00 ET
Vor Bio to Present Clinical Data from First Patient Treated with Trem-cel at 2023 Tandem Meetings
2023-01-12 13:00 ET
Vor Bio to Present at B. Riley Securities’ 3rd Annual Oncology Conference
2022-12-07 12:45 ET
Vor Bio Prices Underwritten Offering of Common Stock and Concurrent Private Placement for Aggregate Proceeds of $115.8 Million
2022-12-07 12:30 ET
First AML Patient Successfully Transplanted with Vor Bio’s Investigational Trem-cel (VOR33) and Tolerated Mylotarg™
2022-11-22 13:00 ET
Vor Bio to Participate in Upcoming Investor Conferences
2022-11-10 21:15 ET
Vor Bio Reports Third Quarter 2022 Financial Results and Provides Company Update
2022-11-01 12:00 ET
Vor Bio to Participate in Upcoming Investor Conferences
2022-10-12 12:00 ET
Vor Bio Appoints Eyal C. Attar, M.D. as Chief Medical Officer
2022-10-11 12:00 ET
Vor Bio Demonstrates Potential of Base and Sequential Multiplex Editing of Hematopoietic Stem Cells for Next-generation AML Treatment
2022-09-28 12:00 ET
Vor Bio Initiates In-house Clinical Manufacturing at Cambridge, MA Headquarters
2022-09-06 20:15 ET
Vor Bio to Participate in Upcoming Investor Conferences
2022-08-11 20:15 ET
Vor Bio Reports Second Quarter 2022 Financial Results and Provides Company Update
2022-08-01 12:00 ET
Vor Bio to Participate in Upcoming Investor Conferences
2022-06-10 12:00 ET
Vor Bio Successfully Demonstrates Multiplex Editing of Hematopoietic Stem Cells for Next-generation AML Treatment Presented at EHA
2022-06-01 12:00 ET
Vor Bio to Participate in Upcoming Investor Conferences
2022-05-12 20:15 ET
Vor Bio Reports First Quarter 2022 Financial Results and Provides Company Update
2022-05-05 12:00 ET
Vor to Participate in Two Upcoming Investor Conferences
2022-04-25 12:00 ET
Vor Bio to Present at Keystone Symposia Precision Genome Engineering Meeting
2022-04-14 20:15 ET
Vor Bio Announces Retirement of Chief Medical Officer
2022-03-22 14:10 ET
Akron BioProducts and Vor Bio to Collaborate on the Development and cGMP Manufacture of Nucleases
2022-03-14 20:30 ET
Vor Bio Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Company Update
2022-02-28 13:00 ET
Vor to Participate in Three Upcoming Investor Conferences
2022-02-11 13:00 ET
Vor to Participate in the 11th Annual SVB Leerink Global Healthcare Conference
2022-01-04 13:00 ET
Vor to Participate in Two Upcoming Investor Conferences
2021-11-29 13:00 ET
Vor to Participate in the JMP Securities Hematology and Oncology Summit
2021-11-19 21:01 ET
Vor to Participate in Piper Sandler 33rd Virtual Annual Healthcare Conference
2021-11-10 21:10 ET
Vor Reports Third Quarter 2021 Financial Results and Provides Company Update
2021-11-09 13:30 ET
Vor to Present New Data on its Cell and Genome Engineering Platform at SITC Annual Meeting
2021-11-08 13:00 ET
Vor to Participate in Two Upcoming Investor Conferences
2021-11-04 13:15 ET
Vor to Present New Platform and Preclinical Data at ASH
2021-10-19 11:00 ET
Vor to Present Data from its Novel Cell and Genome Engineering Platform at ESGCT
2021-10-12 12:00 ET
Vor Strengthens Leadership Team with Addition of Dr. Veit Schmelmer as SVP of Program and Alliance Management
2021-09-10 06:00 ET
PureTech Founded Entity Vor Biopharma Announces VOR33 Granted U.S. FDA Fast Track Designation for Acute Myeloid Leukemia
2021-09-09 12:00 ET
VOR33 Granted U.S. FDA Fast Track Designation for AML
2021-09-02 12:00 ET
Vor to Participate in Three Upcoming Investor Conferences
2021-08-09 20:05 ET
Vor Reports Second Quarter 2021 Financial Results and Provides Company Update
2021-07-09 11:00 ET
PureTech Founded Entity Vor Biopharma Announces Collaboration with Janssen to Develop Engineered Hematopoietic Stem Cell Transplants Combined with a Bi-Specific Antibody Therapy for Acute Myeloid Leukemia (AML)
2021-07-08 12:00 ET
Vor Biopharma Announces Collaboration with Janssen to Develop Engineered Hematopoietic Stem Cell Transplants Combined With a Bi-Specific Antibody Therapy for Acute Myeloid Leukemia (AML)
2021-06-17 12:00 ET
Vor to Build-Out State-of-the-Art Clinical Manufacturing Facility Capable of Supporting Multiple Cell Therapy Programs
2021-06-11 12:00 ET
Vor Biopharma Names Matthew R. Patterson as Chairman and Promotes Tania Philipp
2021-06-10 12:00 ET
Vor to Develop Multi-Targeted CAR-Ts with Abound Bio
2021-05-25 20:10 ET
Vor Biopharma to Present at Jefferies and Goldman Sachs Investor Conferences
2021-05-06 20:08 ET
Vor Reports First Quarter 2021 Financial Results and Provides Company Update
2021-04-28 12:00 ET
Vor To Present on VOR33 Manufacturing Scale-Up and Off-Target Editing at ASGCT
2021-03-25 20:35 ET
Vor Reports Fiscal Year 2020 Financial Results
2021-03-05 20:00 ET
Vor Biopharma to Present at the Barclays Global Healthcare Conference
2021-03-01 20:45 ET
Vor Biopharma Announces Participation at Cowen 41st Annual Health Care Conference
2021-02-10 07:00 ET
PureTech Founded Entity Vor Biopharma Closes Over $200M Initial Public Offering
2021-02-09 21:05 ET
Vor Biopharma Closes Over $200M Initial Public Offering, Including Full Exercise of Option to Purchase Additional Shares
2021-02-05 11:50 ET
PureTech Founded Entity Vor Biopharma Announces Pricing of Initial Public Offering
2021-02-05 11:33 ET
Vor Biopharma Announces Pricing of Initial Public Offering

SEC forms

Show financial reports only

SEC form 8
2025-09-17 13:00 ET
Vor Biopharma Inc. published news for 2025 q2
SEC form 8
2025-09-17 13:00 ET
Vor Biopharma Inc. published news for 2025 q2
SEC form 8
2025-09-02 14:43 ET
Vor Biopharma Inc. published news for 2025 q2
SEC form 8
2025-09-02 14:43 ET
Vor Biopharma Inc. published news for 2025 q2
SEC form 10
2025-08-12 20:02 ET
Vor Biopharma Inc. reported for 2025 q2
SEC form 10
2025-05-14 20:02 ET
Vor Biopharma Inc. reported for 2025 q1
SEC form 10
2025-05-14 00:00 ET
Vor Biopharma Inc. reported for 2025 q1
SEC form 10
2025-03-20 16:01 ET
Vor Biopharma Inc. reported for 2024 q4
SEC form 10
2025-03-20 00:00 ET
Vor Biopharma Inc. reported for 2024 q4
SEC form 10
2024-11-07 16:01 ET
Vor Biopharma Inc. reported for 2024 q3
SEC form 10
2024-08-08 16:01 ET
Vor Biopharma Inc. reported for 2024 q2
SEC form 10
2024-08-08 00:00 ET
Vor Biopharma Inc. reported for 2024 q2
SEC form 10
2024-05-09 00:00 ET
Vor Biopharma Inc. reported for 2024 q1
SEC form 10
2024-03-20 16:00 ET
Vor Biopharma Inc. reported for 2023 q4
SEC form 10
2024-03-20 00:00 ET
Vor Biopharma Inc. reported for 2023 q4
SEC form 10
2023-11-07 16:00 ET
Vor Biopharma Inc. reported for 2023 q3
SEC form 10
2023-11-07 00:00 ET
Vor Biopharma Inc. reported for 2023 q3
SEC form 10
2023-08-10 16:01 ET
Vor Biopharma Inc. reported for 2023 q2
SEC form 10
2023-08-10 00:00 ET
Vor Biopharma Inc. reported for 2023 q2
SEC form 6
2023-06-09 07:41 ET
Vor Biopharma Inc. published news for 2023 q1
SEC form 10
2023-05-11 16:02 ET
Vor Biopharma Inc. reported for 2023 q1
SEC form 10
2023-05-11 00:00 ET
Vor Biopharma Inc. reported for 2023 q1
SEC form 6
2023-04-14 16:03 ET
Vor Biopharma Inc. published news for 2023 q1
SEC form 6
2023-04-14 16:01 ET
Vor Biopharma Inc. published news for 2023 q1
SEC form 10
2023-03-23 16:05 ET
Vor Biopharma Inc. reported for 2022 q4
SEC form 10
2023-03-23 00:00 ET
Vor Biopharma Inc. reported for 2022 q4
SEC form 6
2023-02-16 12:13 ET
Vor Biopharma Inc. published news for 2022 q4
SEC form 6
2022-12-23 16:07 ET
Vor Biopharma Inc. published news for 2022 q3
SEC form 6
2022-12-14 16:32 ET
Vor Biopharma Inc. published news for 2022 q3
SEC form 6
2022-12-07 16:59 ET
Vor Biopharma Inc. published news for 2022 q3
SEC form 6
2022-12-07 07:36 ET
Vor Biopharma Inc. published news for 2022 q3
SEC form 6
2022-11-29 10:25 ET
Vor Biopharma Inc. published news for 2022 q3
SEC form 10
2022-11-10 16:06 ET
Vor Biopharma Inc. reported for 2022 q3
SEC form 10
2022-11-10 00:00 ET
Vor Biopharma Inc. reported for 2022 q3
SEC form 10
2022-08-11 16:07 ET
Vor Biopharma Inc. reported for 2022 q2
SEC form 10
2022-08-11 00:00 ET
Vor Biopharma Inc. reported for 2022 q2
SEC form 6
2022-06-17 16:00 ET
Vor Biopharma Inc. published news for 2022 q1
SEC form 10
2022-05-12 16:06 ET
Vor Biopharma Inc. reported for 2022 q1
SEC form 10
2022-05-12 00:00 ET
Vor Biopharma Inc. reported for 2022 q1
SEC form 6
2022-04-28 08:30 ET
Vor Biopharma Inc. published news for 2022 q1
SEC form 6
2022-04-14 16:01 ET
Vor Biopharma Inc. published news for 2022 q1
SEC form 10
2022-03-14 16:13 ET
Vor Biopharma Inc. published news for 2021 q4
SEC form 10
2022-03-14 00:00 ET
Vor Biopharma Inc. published news for 2021 q4
SEC form 10
2021-11-10 16:06 ET
Vor Biopharma Inc. published news for 2021 q3
SEC form 10
2021-11-10 00:00 ET
Vor Biopharma Inc. published news for 2021 q3
SEC form 10
2021-08-09 16:03 ET
Vor Biopharma Inc. published news for 2021 q2
SEC form 10
2021-08-09 00:00 ET
Vor Biopharma Inc. published news for 2021 q2
SEC form 6
2021-06-17 08:13 ET
Vor Biopharma Inc. published news for 2021 q1
SEC form 10
2021-05-06 16:02 ET
Vor Biopharma Inc. published news for 2021 q1
SEC form 10
2021-05-06 00:00 ET
Vor Biopharma Inc. published news for 2021 q1
SEC form 10
2021-03-25 16:01 ET
Vor Biopharma Inc. published news for 2020 q4
SEC form 6
2021-02-09 16:21 ET
Vor Biopharma Inc. published news for 2020 q4